ReposiTrak (NYSE:TRAK) CEO Randall Fields Sells 4,700 Shares

Key Points

• CEO Randall Fields of ReposiTrak sold 4,700 shares at an average price of $15.71, representing a 7.56% decrease in his position, leaving him with 57,500 shares valued at approximately $903,325.
• ReposiTrak reported a net margin of 30.55% and earnings of $0.09 per share for the most recent quarter, with revenue totaling $5.76 million.
• Institutional investors own 27.35% of ReposiTrak's stock, with notable increases in holdings from companies like BNP Paribas Financial Markets and Tower Research Capital LLC.

ReposiTrak Inc. (NYSE:TRAK - Get Free Report) CEO Randall Fields sold 4,700 shares of the firm's stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $15.71, for a total transaction of $73,837.00. Following the sale, the chief executive officer directly owned 57,500 shares in the company, valued at approximately $903,325. The trade was a 7.56% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

ReposiTrak Stock Performance

TRAK stock traded up $0.90 during midday trading on Wednesday, reaching $15.72. 178,124 shares of the company were exchanged, compared to its average volume of 51,851. The company has a current ratio of 6.03, a quick ratio of 6.03 and a debt-to-equity ratio of 0.01. ReposiTrak Inc. has a 1-year low of $13.86 and a 1-year high of $25.01. The company's 50-day moving average price is $16.81. The company has a market capitalization of $287.36 million, a P/E ratio of 44.92 and a beta of 0.47.

ReposiTrak (NYSE:TRAK - Get Free Report) last released its quarterly earnings data on Monday, September 29th. The company reported $0.09 earnings per share for the quarter. ReposiTrak had a net margin of 30.55% and a return on equity of 14.35%. The company had revenue of $5.76 million for the quarter.

Institutional Trading of ReposiTrak

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets raised its holdings in ReposiTrak by 63.5% during the second quarter. BNP Paribas Financial Markets now owns 1,633 shares of the company's stock worth $32,000 after purchasing an additional 634 shares in the last quarter. Ingalls & Snyder LLC increased its holdings in shares of ReposiTrak by 1.3% in the 2nd quarter. Ingalls & Snyder LLC now owns 198,714 shares of the company's stock valued at $3,905,000 after acquiring an additional 2,554 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of ReposiTrak by 397.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,620 shares of the company's stock valued at $71,000 after acquiring an additional 2,892 shares during the period. Ellsworth Advisors LLC increased its holdings in shares of ReposiTrak by 10.6% in the 1st quarter. Ellsworth Advisors LLC now owns 31,289 shares of the company's stock valued at $634,000 after acquiring an additional 2,997 shares during the period. Finally, American Century Companies Inc. increased its holdings in shares of ReposiTrak by 17.4% in the 2nd quarter. American Century Companies Inc. now owns 23,344 shares of the company's stock valued at $459,000 after acquiring an additional 3,455 shares during the period. Institutional investors and hedge funds own 27.35% of the company's stock.

About ReposiTrak

Park City Group, Inc, a software-as-a-service provider, designs, develops, and markets proprietary software products in North America. The company offers ReposiTrak MarketPlace, a supplier discovery and B2B e-commerce solution; ReposiTrak Compliance and Food Safety solutions, which reduces potential regulatory and legal risk from their supply chain partners; and ReposiTrak Supply Chain solutions that enables customers to manage relationships with suppliers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.